Dr Misghina Tekeste Weldegiorgis
Conjoint Associate Lecturer

Dr Misghina Tekeste Weldegiorgis

2012 - 2017    PhD, University of Groningen, dissertation title "Evaluation of renal endpoints in nephrology trials" 

2010 - 2014    MSc in Pharmacoepidemiology, Utrecht University, dissertation title "Pharmacogenetics of aspirin in secondary acute coronary syndromes"

2002 - 2008    BSc in Pharmacy, University of Asmara, dissertation title "Prevalence and treatment of breast cancer in Asmara"

School of Medical Sciences

Misghina Weldegiorgis is an epidemiologist and medical statistician at The George Institute for Global Health at the University of Oxford, and conjoint lecturer at the University of New South Wales Sydney. His main research interests are in the epidemiology of kidney and cardiovascular diseases. His current research projects investigate modifiable social and clinical risk factors associated with the development and/or progression of kidney diseases using ‘Big Data’ – CPRD, and systematic review and meta-analysis of published studies.

Misghina completed his BSc degree in pharmacy from the University of Asmara and then worked as a pharmacist in Orotta National Referral Hospital and drug evaluation officer in the Ministry of Health, Eritrea, prior to relocating to the Netherlands to pursue his academic interest. He was awarded MSc scholarship by the Dutch Ministry of Education, Culture & Science, and he completed his MSc degree in epidemiology (specialized in pharmacoepidemiology) at Utrecht University. Subsequently, he was awarded PhD fellowship by the Groningen University Institute for Drug Exploration (GUIDE) and completed his doctoral degree in ‘Evaluation of renal endpoints in nephrology trials’. 

Misghina has experience in analyzing and interpreting a large number of clinical trial and clinical practice databases, such as BENEDICT, RENAAL, IDNT, REIN, ROAD, ESBARI, STENO, PREVEND, GIANTT, PHARMO, and CPRD. 

Department of Epidemiology and Biostatistics | School of Public Health | Imperial College London | St Mary’s Campus | Norfolk Place | London W2 1PG | United Kingdom


  • Journal articles | 2021
    Gregg EW; Sophiea MK; Weldegiorgis M, 2021, 'Diabetes and COVID-19: Population Impact 18 Months Into the Pandemic.', Diabetes Care, http://dx.doi.org/10.2337/dci21-0001
    Journal articles | 2021
    Neuen BL; Weldegiorgis M; Herrington WG; Ohkuma T; Smith M; Woodward M, 2021, 'Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression', American Journal of Kidney Diseases, http://dx.doi.org/10.1053/j.ajkd.2021.02.335
    Journal articles | 2020
    Weldegiorgis M; Woodward M, 2020, 'Correction to: The impact of hypertension on chronic kidney disease and end-stage renal disease is greater in men than women: a systematic review and meta-analysis (BMC Nephrology, (2020), 21, 1, (506), 10.1186/s12882-020-02151-7)', BMC Nephrology, vol. 21, http://dx.doi.org/10.1186/s12882-020-02199-5
    Journal articles | 2020
    Weldegiorgis M; Woodward M, 2020, 'The impact of hypertension on chronic kidney disease and end-stage renal disease is greater in men than women: a systematic review and meta-analysis', BMC Nephrology, vol. 21, http://dx.doi.org/10.1186/s12882-020-02151-7
    Journal articles | 2020
    Weldegiorgis M; Smith M; Herrington WG; Bankhead C; Woodward M, 2020, 'Socioeconomic disadvantage and the risk of advanced chronic kidney disease: Results from a cohort study with 1.4 million participants', Nephrology Dialysis Transplantation, vol. 35, pp. 1562 - 1570, http://dx.doi.org/10.1093/ndt/gfz059
    Journal articles | 2019
    Coresh J; Heerspink HJL; Sang Y; Matsushita K; Arnlov J; Astor BC; Black C; Brunskill NJ; Carrero JJ; Feldman HI; Fox CS; Inker LA; Ishani A; Ito S; Jassal S; Konta T; Polkinghorne K; Romundstad S; Solbu MD; Stempniewicz N; Stengel B; Tonelli M; Umesawa M; Waikar SS; Wen CP; Wetzels JFM; Woodward M; Grams ME; Kovesdy CP; Levey AS; Gansevoort RT; Appel LJ; Greene T; Chen TK; Chalmers J; Arima H; Perkovic V; Levin A; Djurdjev O; Tang M; Nally J; Navaneethan SD; Schold JD; Weldegiorgis M; Herrington WG; Smith M; Hsu CY; Hwang SJ; Chang AR; Kirchner HL; Green JA; Ho K; Marks A; Prescott G; Clark LE; Fluck N; Shalev V; Chodick G; Blankestijn PJ; Van Zuilen A; Van den Brand JA; Sarnak MJ; Bottinger E; Nadkarni GN; Ellis SG; Nadukuru R; Metzger M; Flamant M; Houillier P; Haymann JP; Froissart M; Kenealy T; Elley RC; Collins JF; Drury PL; Cuddeback JK; Ciemins EL; Stempniewicz R; Nelson RG; Knowler WC; Bakker SJ; Major RW; Medcalf JF; Shepherd D; Barrett-Connor E; Bergstrom J; Ix JH; Molnar MZ; Sumida K; de Zeeuw D; Brenner B; Qureshi AR; Elinder CG; Runesson B; Evans M; Segelmark M; Stendahl M; Schön S; Naimark DM; Tangri N, 2019, 'Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies', The Lancet Diabetes and Endocrinology, vol. 7, pp. 115 - 127, http://dx.doi.org/10.1016/S2213-8587(18)30313-9
    Journal articles | 2018
    Smith M; Herrington WG; Weldegiorgis M; Hobbs FR; Bankhead C; Woodward M, 2018, 'Change in Albuminuria and Risk of Renal and Cardiovascular Outcomes: Natural Variation Should Be Taken into Account', Kidney International Reports, vol. 3, pp. 939 - 949, http://dx.doi.org/10.1016/j.ekir.2018.04.004
    Journal articles | 2018
    Weldegiorgis M; de Zeeuw D; Li L; Parving HH; Hou FF; Remuzzi G; Greene T; Heerspink HJL, 2018, 'Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy', American Journal of Kidney Diseases, vol. 71, pp. 91 - 101, http://dx.doi.org/10.1053/j.ajkd.2017.08.010
    Journal articles | 2017
    Weldegiorgis M; de Zeeuw D; Dwyer JP; Mol P; Heerspink HJL, 2017, 'Is chronic dialysis the right hard renal end point to evaluate renoprotective drug effects?', Clinical Journal of the American Society of Nephrology, vol. 12, pp. 1595 - 1600, http://dx.doi.org/10.2215/CJN.09590916
    Journal articles | 2015
    Weldegiorgis M; De Zeeuw D; Heerspink HJL, 2015, 'Renal end points in clinical trials of kidney disease', Current Opinion in Nephrology and Hypertension, vol. 24, pp. 284 - 289, http://dx.doi.org/10.1097/MNH.0000000000000118
    Journal articles | 2014
    Lambers Heerspink HJ; Weldegiorgis M; Inker LA; Gansevoort R; Parving HH; Dwyer JP; Mondal H; Coresh J; Greene T; Levey AS; De Zeeuw D, 2014, 'Estimated GFR decline as a surrogate end point for kidney failure: A post hoc analysis from the reduction of end points in non-insulin-dependent diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT)', American Journal of Kidney Diseases, vol. 63, pp. 244 - 250, http://dx.doi.org/10.1053/j.ajkd.2013.09.016
    Journal articles | 2013
    Weldegiorgis M; de Zeeuw D; Greene T; Li L; Rossing P; Smink P; Heerspink HL, 2013, 'PS11 - 1. Longitudinal eGFR trajectories in patients with type 2 diabetes', Nederlands Tijdschrift voor Diabetologie, vol. 11, pp. 162 - 162, http://dx.doi.org/10.1007/s12467-013-0107-6
  • Conference Abstracts | 2020
    Neuen B; Weldegiorgis M; Herrington W; Okhuma T; Smith M; Woodward M, 2020, 'COMBINED CHANGES IN GLOMERULAR FILTRATION RATE AND ALBUMINURIA AND RISK OF KIDNEY DISEASE PROGRESSION IN ROUTINE CLINICAL PRACTICE', in NEPHROLOGY, WILEY, Vol. 25, pp. 23 - 24, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000592647200053&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1